Biomedical engineers at Duke University have developed a new approach to delivering GLP-1 medications orally that does not require fasting and maintains their efficacy. The technique could also be useful for any pharmaceutical based on peptides such as insulin or treatments for irritable bowel syndrome, HIV and osteoporosis.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗